The 5HT3 antagonists are a new class of anti-emetic which act by blocking 5HT3 receptors both centrally and in the gastrointestinal tract (Costall et al., 1986; Miner et al., 1986) .
Ondansetron (GR38032F, Glaxo Ltd) is a 5HT3 antagonist which has been shown to be effective in preventing the emesis associated with cancer chemotherapy (Cunningham et al., 1987; Kriss et al., 1988) . However, there remain patients whose symptoms are inadequately controlled by Ondansetron or conventional agents used alone and this study examines the effect of a combination of Ondansetron plus dexamethasone in such a group. The patients entered in the study continued to receive the same chemotherapy which had failed previous anti-emetic prophylaxis ( (Armitage & Berry, 1987) .
Fourteen patients were entered in the study between June and October 1988 and their characteristics are shown in Early clinical trials have confirmed the effectiveness of 5HT3 antagonists in controlling the emesis associated with cytotoxic chemotherapy (Cunningham et al., 1987; Kriss et al., 1988; Smith et al., 1990) . However, there remain some patients who are inadequately controlled by these agents used alone despite the maintenance of pharmacological serum levels of drug (Smith et al., 1990) . It is likely that in such patients several different mechanisms are responsible for inducing vomiting and therefore in order to achieve optimum symptomatic control combinations of anti-emetics with separate modes of action are required. For this study dexamethasone was chosen for use in conjunction with Ondansetron because it is known to be an effective antiemetic (Kris et al., 1985) and although the precise mechanism of action of dexamethasone is unknown there is no evidence that it interacts with dopaminergic or 5HT3 receptors. In addition, when used for short periods it is largely free from side-effects.
This study shows that 90% of patients failing both dexamethasone and single agent Ondansetron responded to the combination of the two drugs suggesting major synergism between these agents. Cunningham et al. (1989) have also made this observation.
Ondansetron plus dexamethasone is an easily administered, non-toxic regimen which is effective in controlling emesis in patients refractory to conventional therapy. A randomised trial is now in progress to confirm whether this combination is active in patients treated with cisplatin at doses of 100-12Omgm0-2 Correspondence: D.B. Smith.
